Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00722553
Recruitment Status : Completed
First Posted : July 25, 2008
Results First Posted : July 17, 2012
Last Update Posted : May 10, 2013
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc

Brief Summary:
The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of advanced or metastatic bladder cancer. The study will also investigate the safety of pralatrexate with vitamin B12 and folic acid in this patient population. Additionally, this study includes the collection of blood samples to investigate the pharmacokinetics (PK) of pralatrexate in this patient population (PK is the activity of a drug in the body over a period of time, including how the drug is absorbed, distributed in the body, localized in the tissues, and excreted from the body).

Condition or disease Intervention/treatment Phase
Carcinoma, Transitional Cell Bladder Cancer Bladder Neoplasm Drug: Pralatrexate Injection Dietary Supplement: Vitamin B12 Dietary Supplement: Folic Acid Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Single-Arm Study of Pralatrexate in Patients With Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
Study Start Date : July 2008
Actual Primary Completion Date : April 2011
Actual Study Completion Date : September 2011

Intervention Details:
    Drug: Pralatrexate Injection

    Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride).

    Initial dose: 190 mg/m2

    Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity.

    Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.

    Other Names:
    • PDX
    • Pralatrexate
    • (RS)-10-propargyl-10-deazaaminopterin
    Dietary Supplement: Vitamin B12

    1 mg intramuscular injection

    Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.

    Other Name: Cyanocobalamin
    Dietary Supplement: Folic Acid

    1-1.25 mg orally

    Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate.

    Other Names:
    • Vitamin B9
    • Folate
    • Folacin

Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no more than every 12 weeks (+/- 1 week) if treatment has ended for up to 2 years after enrollment. ]
    The number of patients with a best overall confirmed response of either complete response (CR) or partial response (PR)

Secondary Outcome Measures :
  1. Duration of Response (DOR) [ Time Frame: Measured from the first day of documented response for up to 2 years after enrollment. ]
    Duration of time from when tumor measurement criteria were met for CR or PR (whichever status was recorded first) until the first date that recurrent disease or progressive disease (PD) or death was objectively documented. Progression is defined, using RECIST, as an increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline. Calculated for those patients with a best overall confirmed or unconfirmed response of CR or PR.

  2. Clinical Benefit Rate (CBR) [ Time Frame: Assessed at the end of each even-numbered cycle (every 8 weeks) or per standard of care, but no more than every 12 weeks (+/- 1 week) if treatment has ended, for up to 2 years after enrollment. ]
    The number of patients with a best confirmed or unconfirmed response of CR, PR, or stable disease (SD) for at least 24 weeks (approximately 5.5 months)

  3. Progression Free Survival (PFS) [ Time Frame: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no more than every 12 weeks (+/- 1 week) if treatment has ended, for up to 2 years after enrollment. ]
    Length of time from study day 1 to the date of radiological evidence of PD (date of computed tomography [CT] or magnetic resonance imaging [MRI] scan, whichever indicates PD) or death, regardless of cause.

  4. Overall Survival (OS) [ Time Frame: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care if treatment has ended (at least every 12 weeks) for up to 2 years after enrollment. After PD or start of subsequent treatment, OS will be assessed every 4 months. ]
    The number of days from study day 1 to death. Patients who had not died (no record of death) or were lost to follow-up were censored at the date of last contact.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed transitional cell carcinoma of the urinary bladder. Fine needle aspirate will not be accepted.
  • Relapsed or progressed after treatment with a platinum- and/or methotrexate-based systemic chemotherapy regimen. No more than 1 prior regimen is permitted for recurrent/metastatic disease. Patients has had a chemotherapy-free interval of ≥ 12 months from last dose if most recent prior chemotherapy was in neoadjuvant/adjuvant setting and has had ≥ 6-month chemotherapy-free interval in recurrent/metastatic setting. Patient has recovered from the toxic effects of prior therapy. Previous intravesical therapy is allowed. Prior surgical resection is allowed, as long as the patient has recovered.
  • Measurable disease outside a previously irradiated region, per Response Evaluation Criteria in Solid Tumors (RECIST).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • At least 18 years of age.
  • Adequate blood, liver, and kidney function as defined by laboratory results.
  • Patient has received 1.0-1.25 mg of oral folic acid daily for at least 7 days of enrollment & 1 mg intramuscular vitamin B12 within 10 weeks of enrollment.
  • Women of childbearing potential have a negative serum pregnancy test within 14 days prior to enrollment and agree to use medically acceptable and effective birth control from enrollment until at least 30 days after the last dose of pralatrexate.
  • Men who are not surgically sterile and whose partner is of childbearing potential must use medically safe and effective birth control start of pralatrexate until at least 90 days after the last dose of pralatrexate.
  • Accessible for repeat dosing and follow up.
  • Give written informed consent.

Exclusion Criteria:

  • Active concurrent primary malignancy or prior malignancies occurring within 5 years (except non-melanoma skin cancer, in situ carcinoma of the cervix, or occult, indolent carcinoma of the prostate). If there is a history of prior malignancies other than those exceptions listed above, the patient must be disease free for ≥ 5 years. Patients with other prior malignancies < 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease. In the case of a single extrapelvic metastatic site, irrespective of the patient having a history of previous malignancy, a biopsy proof of the metastatic diseased organ will be necessary.
  • More than 1 previous regimen for recurrent/metastatic disease.
  • Evidence of clinically significant active third-space phenomenon
  • Use of investigational drugs, biologics, or devices within 28 days prior to study enrollment.
  • Previous exposure to other antifolates, including pralatrexate. Previous methotrexate is allowed, only if it was part of an M-VAC or MCV regimen.
  • Women who are pregnant or breastfeeding.
  • Congestive Heart Failure Class III/IV according to New York Heart Association (NYHA) Functional Classification.
  • Uncontrolled hypertension.
  • Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of < 100 mm3 or detectable viral load within the past 3 months, and receiving combination anti-retroviral therapy.
  • Central nervous system metastatic disease.
  • Major surgery within 2 weeks of study enrollment.
  • Radiation therapy (RT) within 4 weeks (within 3 months for RT to the pelvis) prior to study enrollment.
  • Active infection or any serious underlying medical condition, which would impair the ability of the patient to receive protocol treatment.
  • Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent or limit study compliance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00722553

United States, Arizona
The University of Arizona Health Sciences Center
Tucson, Arizona, United States, 85724
United States, Georgia
Peachtree Hematology/Oncology Consultants
Atlanta, Georgia, United States, 30318
United States, New York
University of Rochester Cancer Center
Rochester, New York, United States, 14642
United States, Utah
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Centro de Terapia Radiante Cumbres (CAICI)
Rosario, Santa Fe, Argentina, 2000
IONC (Instituto Oncológuci de Cordoba)
Cordoba, Argentina, X5004BAL
Algemeen Ziekenhuis Middelheim
Antwerp, Belgium, 2020
Institut Jules Bordet
Brussels, Belgium, 1000
CH Split Clinic of Oncology and Radiotherapy
Split, Croatia, 21000
CHU Zagreb University Hospital Center Rebro in Zagreb
Zagreb, Croatia, 10000
Clinic of Oncology and Nuclear Medicine, CH "Sestre Milosrdnice"
Zagreb, Croatia, 10000
Institut Sainte Catherine
Avignon, France, 84082
Centre Oscar Lambret
Lille Cedex, France, 59020
Centre Hospitalier Rene Dubos
Pontoise, France, 95301
Hopital Foch
Suresnes, France
Institut Gustave Roussy
Villejuif Cedex, France, 94 805
Ciutat Sanitari de Vall d'Hebron
Barcelona, Spain, 08035
Hospital Del Mar - Barcelona
Barcelona, Spain, 8003
Hospital Virgen del Rocio
Sevilla, Spain, 41013
Sponsors and Collaborators
Spectrum Pharmaceuticals, Inc
Study Director: Garry Weems, Pharm.D. Spectrum Pharmaceuticals, Inc

Responsible Party: Spectrum Pharmaceuticals, Inc Identifier: NCT00722553     History of Changes
Other Study ID Numbers: PDX-011
2007-004671-19 ( EudraCT Number )
First Posted: July 25, 2008    Key Record Dates
Results First Posted: July 17, 2012
Last Update Posted: May 10, 2013
Last Verified: May 2013

Keywords provided by Spectrum Pharmaceuticals, Inc:
Transitional Cell Carcinoma of the Urinary Bladder
Transitional Cell Carcinoma
Bladder Cancer
Urinary Bladder Cancer

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urologic Diseases
Folic Acid
Vitamin B 12
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents